Gynecomastia statistics: how common it really is, and why the answer runs from 1% to 65%

You notice a firm area behind the nipple, search for a percentage, and get answers from 1% to 65%. They are not measuring the same thing.

Gynecomastia is common, but the number changes with the definition. On the same chest scans, changing the glandular-tissue cut-off changed the result from 52.1% to 11.2%.

Key numbers

• 52.1% vs 11.2% on the same pediatric CT scans when the cut-off changed from 5 mm to 20 mm. Source
• 65% of 214 men in a 1984 study of hospitalized adults, found by touch. Source
• 55 of 100 men had microscopic gynecomastia at autopsy, and none had shown clinical signs. Source
• More than 90% of pubertal cases resolve on their own within 24 months, according to the EAA guideline. Source
• 1.08% of Israeli boys aged 12–15 had a recorded diagnosis in a national health-fund database. Source
• 26,430 surgeries were reported in the ASPS 2024 release, the most common male cosmetic surgical procedure in that table. Source
• 0.11% of 5,113 removed breasts contained invasive carcinoma in a Dutch pathology series. Source

Table of contents

• How common is gynecomastia, really?
• Where does the 65% of men statistic come from?
• How common is gynecomastia in teens, and does it go away?
• Is it gland or fat?
• What causes gynecomastia in adult men?
• Is gynecomastia linked to breast cancer?
• How many men get gynecomastia surgery?
• How to cite this page
• The bottom line
• Sources

How common is gynecomastia, really?

Gynecomastia is common, but prevalence is not one fixed property of the male body. The European Academy of Andrology (EAA) guideline reports published prevalence from 32% to 65% and says the figure depends on age and on the criteria used; it is not a share of men with visible enlargement. Source

The clinical definition is palpable glandular tissue. Fat is called lipomastia, or pseudogynecomastia, and a breast exam is needed to distinguish them.

The definition sets the number. The same scans produced 52.1%, 37.4%, or 11.2% with 5, 10, or 20 mm glandular cut-offs. Recorded diagnoses are lower because they count people seen and coded, not every person with tissue.

High palpation and autopsy figures are real; they answer a broader question than visible chest enlargement.

Where does the 65% of men statistic come from?

The 65% figure comes from a 1984 examination of 214 hospitalized men aged 27–92. It is not a general-population estimate and does not mean 65% of men visibly have enlarged breasts. Source

Palpable tissue peaked at 72% among men aged 50–69, versus 54% at 30–49 and 47% at 70–89. Disease and medication effects could not be separated; more than 80% of men with BMI 25 kg/m² or higher had palpable gynecomastia.

An ASPS blog attributes roughly 65% of men aged 27–92 to an NIH study, while the source is the hospitalized-men paper; it omits the hospitalized and palpable qualifiers. An American Family Physician review changes the age range to 50–80, although the original covered 27–92 and reported 72% at ages 50–69. ASPS source AAFP source

The EAA's 32%–65% range is safer because age and criteria drive the result.

The 65% result deserves citation; its denominator and definition deserve equal prominence.

How common is gynecomastia in teens, and does it go away?

Pubertal gynecomastia is common and usually temporary. The EAA guideline says about 50% of mid-pubertal boys experience it and more than 90% resolve within 24 months; a Cincinnati cohort found 48.5% over repeated exams, and a Danish cohort 49% over up to 8 years. Source

A Bulgarian one-time exam using at least 1 cm found 3.93% among boys aged 10–19. A Turkish study found 34.6% overall, 60.2% at pubertal stage 4, and 61.1% at age 14. One catches a moment; repeated exams catch tissue that comes and goes.

Biro et al. concluded it usually lasts less than 1 year; Endotext says it usually resolves within 3 years and estimates around 20% with residual tissue at age 20. Endotext also says that once gynecomastia has been present for more than six months, regression is unlikely because the tissue becomes more fibrotic. Endotext

Chest tissue in puberty is one of the most common body changes boys go through, and the fear of being noticed is usually bigger than the noticing; do people notice gyno? looks at that directly.

Most pubertal cases resolve, but “most” is not a promise; time course and examination still matter.

Is it gland or fat?

Gynecomastia means palpable glandular tissue; pseudogynecomastia means fat without the same glandular finding. A breast exam is needed to tell them apart, and no population study says what share of enlarged male chests are gland rather than fat. Source

Among 124 pubertal boys at a German outpatient clinic, ultrasound classified 86 as true gynecomastia and 38 as pseudogynecomastia. That shows both findings in referrals, not the split in all boys. Source

In the hospitalized 1984 sample, breast-tissue diameter rose with BMI, but palpation cannot fully separate fat from gland. In an Israeli CT study, glandular diameter did not correlate with BMI, and radiological gynecomastia was associated with cirrhosis and dialysis but not obesity. Source

If the tissue is mostly fat, how to lose chest fat is the relevant guide; only an examination can confirm which one you have.

Clinic samples show what gets referred, not how the whole population divides between gland and fat.

What causes gynecomastia in adult men?

Adult-onset gynecomastia deserves a medical check because investigations often find a cause. The EAA guideline gives about 45%–50% for adult cases, while a Copenhagen referral series found a cause in 43% at onset age 18 or older. Source Source

An AAFP clinical table lists about 25% physiologic, 25% idiopathic, and 10%–25% medication or substance use; an evidence-based review estimates drugs cause about 10%–25% of clinical cases. These are clinical-series estimates, not population shares. AAFP source Source

In the RALES heart-failure trial, gynecomastia or breast pain was reported in 10% of men on spironolactone versus 1% on placebo; the US label says about 9% developed gynecomastia and describes it as dose-dependent and usually reversible. This is heart-failure evidence, not a prediction for every use. Source DailyMed source

The Propecia hair-loss label found breast tenderness and enlargement no more common than placebo in its clinical studies, while prostate-trial data recorded 0.5% versus 0.1% in year 1 and 1.8% versus 1.1% in years 2–4; a separate trial reported 2.2% on finasteride versus 0.7% on placebo. The groups were men with enlarged prostate, not the hair-loss trial population. Source Source

Anabolic steroids appear in clinical data: 52% of 97 British users self-reported gynecomastia, while examination found it in 10 of 27 past users and 2 of 14 current users in an Australian clinic. Our steroid use statistics cover how common use is. Do not stop or change medication based on a statistics page—ask a clinician.

Adult referral numbers identify reasons to investigate, not the cause of every adult case.

Is gynecomastia linked to breast cancer?

Gynecomastia is not considered a premalignant condition, and male breast cancer is rare. That does not mean every lump should be ignored: the EAA guideline still recommends ruling out cancer during evaluation. Source

In Dutch surgical pathology, 0.11% of 5,113 surgically removed gynecomastia breasts contained invasive carcinoma; carcinoma in situ was 0.18%. The denominator is operated breasts, not men, and the youngest patient with invasive cancer was 65. Source

The American Cancer Society estimates about 2,670 US men will be diagnosed with invasive breast cancer in 2026 and about 530 will die from it. It estimates an average lifetime risk of about 1 in 755 for a US man, and fewer than 1% of breast cancers in the US occur in men. ACS source

So the sentence is not “gynecomastia causes cancer.” It is that gynecomastia is usually a benign tissue finding, while a new or concerning lump is a separate medical question that deserves examination.

Rare is not never; the statistics lower panic, not the value of appropriate medical evaluation.

How many men get gynecomastia surgery?

Surgery counts are not prevalence counts. They count people who chose or were referred for an operation; ASPS figures are estimates from member surgeons. The ASPS 2024 release reported 26,430 male breast-reduction procedures, the most common cosmetic surgical procedure among men. Source

2,942 procedures, or 11%, were on patients aged 19 or younger, while 7,554, or 29%, were on men aged 30–39. Most pubertal cases resolve on their own, so adolescent surgery numbers do not tell us that persistence is typical. Source

One release contains conflicting 2023 baselines and growth figures, and the 2025 release restates 2024 as 25,351 while reporting 23,318 male breast reductions for 2025. The safe claim is the ranked procedure count, with the report year named. Source

Outcomes are not a simple before-and-after promise. A systematic review covered 94 studies and 7,294 correction patients with 1,407 complications; an adolescent Boston cohort found complications in 36% of operated breasts, most often residual tissue, contour irregularities, and hematomas. Another Boston study found quality-of-life and self-esteem measures moved from worse than controls at baseline to similar after surgery, while a systematic review judged the treatment evidence very low quality because included studies were non-randomised and at high risk of bias. Source Source Source Source

Surgery data show demand and reported outcomes; they cannot tell you whether an operation is appropriate for one person.

How to cite this page

Suggested citation: Real World Appeal. “Gynecomastia statistics: how common it really is, and why the answer runs from 1% to 65%.” realworldappeal.com, September 2026. https://realworldappeal.com/blog/gynecomastia-statistics

Primary sources are linked throughout so writers, journalists, and students can cite the original studies directly. Data retrieved 13 September 2026.

The bottom line

Gynecomastia is common, particularly around puberty and later adulthood, but “how common” has no honest single answer without naming the definition. Palpation, microscopy, imaging cut-offs, diagnosis codes, and surgery counts produce different denominators; the 65% headline is a real hospitalized-men finding, not a universal visible-enlargement rate.

The definition sets the number.

If the worry is how you come across in an ordinary fitted shirt, Real World Appeal’s free photo read describes the first impression a photo gives. It is not a chest measurement, clinical assessment, or scientific instrument, and it gives no medical diagnosis or personal score.

Sources

• Kanakis GA et al. (European Academy of Andrology) (2019). EAA clinical practice guidelines—gynecomastia evaluation and management. Andrology 7(6):778–793. Linked source
• Nuttall FQ (1979). Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab 48(2):338–340. Linked source
• Niewoehner CB, Nuttall FQ (1984). Gynecomastia in a hospitalized male population. Am J Med 77(4):633–638. Linked source
• Andersen JA, Gram JB (1982). Male breast at autopsy. Acta Pathol Microbiol Immunol Scand A 90(3):191–197. Linked source
• Georgiadis E et al. (1994). Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol 21(6):579–587. Linked source
• Biro FM et al. (1990). Hormonal studies and physical maturation in adolescent gynecomastia. J Pediatr 116(3):450–455. Linked source
• Mieritz MG et al. (COPENHAGEN Puberty Study) (2015). A longitudinal study of growth, sex steroids, and IGF-1 in boys with physiological gynecomastia. J Clin Endocrinol Metab 100(10):3752–3759. Linked source
• Kumanov P et al. (2007). Relationship of adolescent gynecomastia with varicocele and somatometric parameters: a cross-sectional study in 6200 healthy boys. J Adolesc Health 41(2):126–131. Linked source
• Guvenc H et al. (1989). The incidence of pubertal gynecomastia in boys living in the Ankara region. Turk J Pediatr 31(2):123–126. Linked source
• Ilgar M, Unlu S (2022). The prevalence of incidental finding of gynecomastia on thoracic computed tomography in the pediatric age group. J Pediatr Endocrinol Metab 35(3):333–339. Linked source
• Berger O, Hornik-Lurie T, Talisman R (2024). Pubertal gynecomastia incidence among 530,000 boys: a cross sectional population based study. Front Pediatr 12:1367550. Linked source
• Koch T et al. (2020). Marked increase in incident gynecomastia: a 20-year national registry study, 1998 to 2017. J Clin Endocrinol Metab 105(10):dgaa440. Linked source
• Niewoehner CB, Schorer AE (2008). Gynaecomastia and breast cancer in men. BMJ 336(7646):709–713. Linked source
• Swerdloff RS, Ng JCM (Endotext) (2023). Gynecomastia: Etiology, Diagnosis, and Treatment. Endotext [Internet]. Linked source
• Reinehr T et al. (2020). Sex hormone profile in pubertal boys with gynecomastia and pseudogynecomastia. J Clin Endocrinol Metab 105(4):dgaa044. Linked source
• Dickson G (American Academy of Family Physicians) (2012). Gynecomastia. Am Fam Physician 85(7):716–722. Linked source
• Mieritz MG et al. (2017). Gynaecomastia in 786 adult men: clinical and biochemical findings. Eur J Endocrinol 176(5):555–566. Linked source
• Deepinder F, Braunstein GD (2012). Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf 11(5):779–795. Linked source
• Pitt B et al. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES). N Engl J Med 341(10):709–717. Linked source
• Pfizer / US FDA-approved label via NLM DailyMed (2025). ALDACTONE (spironolactone) tablets—US prescribing information. Linked source
• Organon LLC / US FDA-approved label via NLM DailyMed (2024). PROPECIA (finasteride) tablets—US prescribing information. Linked source
• Organon LLC / US FDA-approved label via NLM DailyMed (2026). PROSCAR (finasteride) tablets—US prescribing information. Linked source
• Korkia P, Stimson GV (1997). Indications of prevalence, practice and effects of anabolic steroid use in Great Britain. Int J Sports Med 18(7):557–562. Linked source
• O'Sullivan AJ et al. (2000). Anabolic-androgenic steroids: medical assessment of present, past and potential users. Med J Aust 173(6):323–327. Linked source
• Lapid O, Jolink F, Meijer SL (2015). Pathological findings in gynecomastia: analysis of 5113 breasts. Ann Plast Surg 74(2):163–166. Linked source
• American Cancer Society (2026). Key Statistics for Breast Cancer in Men. Linked source
• American Society of Plastic Surgeons (2025). 2024 Procedural Statistics Release—Cosmetic Surgery Gender Distribution (Male). Linked source
• American Society of Plastic Surgeons (2025). 2024 ASPS Procedural Statistics Release. Linked source
• American Society of Plastic Surgeons (2026). 2025 ASPS Procedural Statistics Release. Linked source
• Innocenti A, Melita D, Dreassi E (2022). Incidence of complications for different approaches in gynecomastia correction: a systematic review of the literature. Aesthetic Plast Surg 46(3):1025–1041. Linked source
• McNamara CT et al. (Boston Children's Hospital) (2022). Complications and quality of life following gynecomastia correction in adolescents and young men. Plast Reconstr Surg 149(6):1062e–1070e. Linked source
• Nuzzi LC et al. (2018). The effect of surgical treatment for gynecomastia on quality of life in adolescents. J Adolesc Health 63(6):759–765. Linked source
• Fagerlund A et al. (2015). Gynecomastia: a systematic review. J Plast Surg Hand Surg 49(6):311–318. Linked source
• American Society of Plastic Surgeons (n.d.). How does gynecomastia affect boys and men at different ages? Linked source